Elan Prialt Clears FDA; Half Of Projected Market Does Not Have Delivery Pump

Elan estimates that more than half of the 120,000 potential users of its non-opioid analgesic Prialt do not already possess an internal drug delivery pump expected to be used in ziconotide administrations